CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Clinical trials for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) trials appear
Sign up with your email to follow new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Major trial tests potential Game-Changer for Tough-to-Treat lung cancer
Disease control Recruiting nowThis large Phase 3 study aims to see if a new drug called PF-08634404, when given with chemotherapy, works better and is as safe as the current standard treatment (pembrolizumab with chemotherapy) for adults with advanced non-small cell lung cancer that has spread. About 1,410 pa…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 19:40 UTC
-
Major trial tests Two-Drug attack on advanced lung cancer
Disease control Recruiting nowThis study is testing whether adding a new drug called Sigvotatug Vedotin to an existing immunotherapy (pembrolizumab) works better than the immunotherapy alone for advanced non-small cell lung cancer. It will involve about 714 adults whose cancer has high levels of a specific pr…
Matched conditions: CARCINOMA, NON-SMALL-CELL LUNG (NSCLC)
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC